Amryt Pharma plc Amryt Receives Ministry Of Health Reimbursement Approval For Lojuxta(R) (lomitapide) In Saudi Arabia

 
TIDMAMYT 
 
   Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta(R) 
(lomitapide) in Saudi Arabia 
 
   DUBLIN, Ireland, and Boston MA, December 17, 2020, Amryt (Nasdaq: AMYT, 
AIM: AMYT), a global, commercial-stage biopharmaceutical company 
dedicated to developing and commercializing novel therapeutics to treat 
patients suffering from serious and life-threatening rare diseases, is 
pleased to announce Ministry of Health reimbursement approval has been 
granted for Lojuxta(R) (lomitapide) in the Kingdom of Saudi Arabia. 
 
   Lojuxta(R) has been approved as an adjunct to a low-fat diet and other 
lipid-lowering treatments, with or without low density lipoprotein (LDL) 
apheresis, to reduce low-density lipoprotein cholesterol (LDL-C) in 
adult patients with homozygous familial hypercholesterolaemia (HoFH). 
 
   Dr Joe Wiley, CEO of Amryt Pharma, commented today:  "We are very 
pleased that the Ministry of Health in the Kingdom of Saudi Arabia has 
approved the reimbursement of Lojuxta(R) which will give Saudi patients 
suffering from HoFH the opportunity to access Lojuxta(R).  Today's news 
represents further progress in our efforts to grow the geographic reach 
of our commercial products in both existing and new territories and to 
make Lojuxta(R) available to HoFH patients in need globally." 
 
   About Amryt 
 
   Amryt is a biopharmaceutical company focused on developing and 
delivering innovative new treatments to help improve the lives of 
patients with rare and orphan diseases. Amryt comprises a strong and 
growing portfolio of commercial and development assets. 
 
   Amryt's commercial business comprises two orphan disease products. 
 
   Amryt's lead development candidate, FILSUVEZ(R) (oleogel S-10) is a 
potential treatment for the cutaneous manifestations of Epidermolysis 
Bullosa ("EB"), a rare and distressing genetic skin disorder affecting 
young children and adults for which there is currently no approved 
treatment.  FILSUVEZ(R) has been selected as the brand name for the 
product. Amryt does not have regulatory approval for FILSUVEZ(R) to 
treat EB. In September and October 2020, Amryt reported positive results 
from its pivotal global Phase 3 trial in EB. The product has been 
granted Rare Pediatric Disease Designation and has also received a Fast 
Track Designation from the U.S. Food and Drug Administration. 
 
   Myalept(R) / Myalepta(R) (metreleptin) is approved in the US (under the 
trade name Myalept(R)) as an adjunct to diet as replacement therapy to 
treat the complications of leptin deficiency in patients with congenital 
or acquired generalized lipodystrophy (GL) and in the EU (under the 
trade name Myalepta(R)) for the treatment of leptin deficiency in 
patients with congenital or acquired GL in adults and children two years 
of age and above and familial or acquired partial lipodystrophy (PL) in 
adults and children 12 years of age and above for whom standard 
treatments have failed to achieve adequate metabolic control. 
Metreleptin is also approved for lipodystrophy in Japan. Generalised and 
partial lipodystrophy are rare disorders characterised by loss or lack 
of adipose tissue resulting in the deficiency of the hormone leptin, 
produced by fat cells and are associated with severe metabolic 
abnormalities including severe insulin resistance, diabetes, 
hypertriglyceridemia and fatty liver disease. 
 
   Juxtapid(R)/ Lojuxta(R) (lomitapide) is approved as an adjunct to a 
low-fat diet and other lipid-lowering medicinal products for adults with 
the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia 
("HoFH") in the US, Canada, Columbia, Argentina and Japan (under the 
trade name Juxtapid(R)) and in the EU and Brazil (under the trade name 
Lojuxta(R)). HoFH is a rare genetic disorder which impairs the body's 
ability to remove low density lipoprotein ("LDL") cholesterol ("bad" 
cholesterol) from the blood, typically leading to abnormally high blood 
LDL cholesterol levels in the body from before birth - often ten times 
more than people without HoFH - and subsequent aggressive and premature 
cardiovascular disease. 
 
   In March 2018, Amryt in-licensed a pre-clinical gene-therapy platform 
technology, AP103, which offers a potential treatment for patients with 
Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also 
potentially relevant to other genetic disorders.  For more information 
on Amryt, including products, please visit www.amrytpharma.com. 
 
   This announcement contains inside information for the purposes of 
article 7 of the Market Abuse Regulation (EU) 596/2014.  The person 
making this notification on behalf of Amryt is Rory Nealon, CFO/COO and 
Company Secretary. 
 
   Forward-Looking Statements 
 
   This press release may contain forward-looking statements containing the 
words "expect", "anticipate", "intends", "plan", "estimate", "aim", 
"forecast", "project" and similar expressions (or their negative) 
identify certain of these forward-looking statements. The 
forward-looking statements in this announcement are based on numerous 
assumptions and Amryt's present and future business strategies and the 
environment in which Amryt expects to operate in the future. 
Forward-looking statements involve inherent known and unknown risks, 
uncertainties and contingencies because they relate to events and depend 
on circumstances that may or may not occur in the future and may cause 
the actual results, performance or achievements to be materially 
different from those expressed or implied by such forward-looking 
statements. These statements are not guarantees of future performance or 
the ability to identify and consummate investments. Many of these risks 
and uncertainties relate to factors that are beyond each of Amryt's 
ability to control or estimate precisely, such as future market 
conditions, the course of the COVID-19 pandemic, currency fluctuations, 
the behaviour of other market participants, the outcome of clinical 
trials, the actions of regulators and other factors such as Amryt's 
ability to obtain financing, changes in the political, social and 
regulatory framework in which Amryt operates or in economic, 
technological or consumer trends or conditions. Past performance should 
not be taken as an indication or guarantee of future results, and no 
representation or warranty, express or implied, is made regarding future 
performance. No person is under any obligation to update or keep current 
the information contained in this announcement or to provide the 
recipient of it with access to any additional relevant information that 
may arise in connection with it. Such forward-looking statements reflect 
the Company's current beliefs and assumptions and are based on 
information currently available to management. 
 
   Contacts 
 
   Joe Wiley, CEO, [phone], [e-mail] 
https://www.globenewswire.com/Tracker?data=RaZu8Id8AuslqF6a1h7cXnzt_MadxcEM2XNXInibshXCUUH_We4ZDvuCppmzrHFmhkHIR6zgKuBVj6Cs_oDFtbPEB6Ck0e41ccgvWd_OVV6Fed0eqa2y9b-ukS1EbYi3 
 
 
   Rory Nealon, CFO/COO, [phone], [e-mail] 
https://www.globenewswire.com/Tracker?data=rPG5OE9m0CpD3PAVLwdBov10qUCNMiaby72LQtF9Hz21Y6wW6vkvfxETKahpIhFsAmI2VyIBeiZ5ci0BKeN7r80A4Ns3X2zItk43aCzWnTJtKicQpznxX1QxSuRkcGYW 
 
 
   Edward Mansfield, Shore Capital, NOMAD, [phone], 
[e-mail] 
 
   Tim McCarthy, LifeSci Advisors, LLC, [phone], 
[e-mail] 
https://www.globenewswire.com/Tracker?data=TnPNoLH36AT8qaaqXxZGiDxinog3irMTzoZscIlSHqRgKP7fktQ3d3rI4GqclCYLBkz99_GhXus4alTogHA-8_hjtsQHOWAhbJCPp4xAkvo= 
 
 
   Amber Fennell, Consilium Strategic Communications, [phone], 
[e-mail] 
https://www.globenewswire.com/Tracker?data=2HsyPS0xPrf06wUN1cNc85I1tXPyKWUza7z2PaIwKr4LU_UFDVs47ohrUw5LwcBlnkR3PdOcjywoSO0hA2pjJGyv1E9B9e0kRwVllg_0HK4n3SxWHpP4Q3N7RSJjm_NO 
 
 
 
 
 

(END) Dow Jones Newswires

December 17, 2020 02:00 ET (07:00 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.